Page 250 of 293: studies 2,491 to 2,500 of 2,926, newest first. Back to the psychedelic-assisted therapy overview
Psychiatric News January 28, 2022 Claire Zilber
Back to table of contents Previous article Next article Ethics CornerFull AccessEthics Committees ReimaginedClaire Zilber, M.D.Claire Zilber, M.D.Published Online:28 Jan 2022https://doi.org/10.1176/appi.pn.2022.2.25The APA and district branch (DB) ethics committees used to stay busy processing complaints from patients, their family members, and colleagues about members who allegedly engaged in...
Family Practice January 24, 2022 James Bailey Sanford
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a...
The Journal of Clinical Psychiatry January 18, 2022 Dan Grossman, Peter S. Hendricks
A research on classic psychedelic–assisted treatments continues to expand, we can expect that findings will sometimes challenge or elucidate long-held conventional beliefs about the purported dangers of these substances. One such notion has been that they precipitate suicidality1 and other self-harm behaviors (eg, jumping off of buildings believing one can fly, walking in front of traffic2) in...
Mental Health Weekly January 17, 2022 Valerie A. Canady
Research is revealing that psychedelics are showing promise as mental health treatment for depression and post‐traumatic stress disorder (PTSD). Psychedelic therapies continue to be studied in clinical trials around the country.
Psychopharmacology January 13, 2022 David A Bender, David J Hellerstein 82 citations
RationaleA broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use.ObjectivesTo use recently published data to assess potential risks and benefits of psychedelic drugs as...
Journal of Psychoactive Drugs January 10, 2022 Nicolas G. Glynos, Jennifer Pierce, Alan K. Davis et al. 39 citations
Fibromyalgia (FM) is a difficult to treat chronic pain condition for which there is strong interest in alternative treatments. There is growing interest in the potential of psychedelic substances (e.g., psilocybin) in conjunction with psychotherapy to treat chronic pain. Via a cross-sectional, anonymous, online survey, we aimed to characterize knowledge, perceptions, and past use of...
Journal of Psychoactive Drugs January 3, 2022 Brianna R. Altman, Mitch Earleywine, Joseph A. de Leo 4 citations
Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin has generated media attention and empirical support for antidepressant effects, but lay impressions of its effectiveness are unclear. Although perceptions of treatment credibility contribute to outcome, beliefs about the credibility of...
Progress in Palliative Care January 2, 2022 A. C. Garcia, L. O. Maia
The healthcare field and society at large are witnessing a resurgence of interest in the effects and applications of psychedelic therapies in a wide range of settings. In the 1950s and 1960s, research was conducted to explore different applications for psychedelics, such as lysergic acid diethylamide (LSD) and mescaline, in the healthcare setting. However, psychedelic research was dramatically...
ABSTRACT BOOK 2022 2022
1. Objetivos: El objetivo principal de este estudio ha sido revisar las distintas drogas psicodélicas que han sido estudiadas hasta el momento como posibles nuevas terapias para el abordaje de trastornos psiquiátricos. Como objetivos secundarios: - Estudiar la psilocybina como tratamiento para la depresión resistente. - Conocer el uso de drogas psicodélicas en pacientes post Covid-19 con...
Current Topics in Behavioral Neurosciences 2022 Amanda J Khan, Ellen Bradley, Aoife O'Donovan et al.
Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or...